Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

“Anti-tumor immune cells are also challenged by nutrient limitation in tumors.” Nutrient limitation in the tumor microenvironment can lead to the metabolic suppression of effector immune cells, ...

Their role in shaping the complex interactions between cancer cells and their microenvironment makes them vital for sustaining tumor development. Additionally, lncRNAs regulate processes such as ...

While novel and more effective treatments continue to increase at a rapid rate, testing platforms that accurately mimic the tumor microenvironment (TME) are lacking. Tumors are complex ecosystems that ...

resulting in alterations in the properties of the tumor microenvironment. Similarly, PDOs – while reflective of a patient’s genomic characteristics – face uncertainties in preserving the phenotype and ...

According to a new report, the global Tumor Microenvironment Market will grow from US$ 1.47 Billion in 2023 to US$ 3.43 billion by 2030 at a compounded annual growth rate (CAGR) of 12.9% during the ...

Further research is needed to understand changes in the ccRCC tumor immune microenvironment and explore potential therapeutic role of integrin after immunotherapy treatment. Genome biology. 2024 Dec ...

The tumor microenvironment (TME) is one of the most formidable obstacles in the fight against cancer. While therapies that target cancer cells have been revolutionary, many patients still do not ...

Without Tsp-1, the tumor microenvironment throws up a slew of defenses that prevent the immune system from curbing the cancer. "These cells secrete so many agents that kill or inhibit activation ...

FMOD promotes integrin-dependent Notch signaling in endothelial cells to enhance their migratory and blood vessel-forming capacity. These findings indicate that DGCs are crucial for supporting tumor ...

integrin antagonist treatments that block the interaction between malignant cells and the ECM has achieved considerable success in pre-clinical models. Administration of anti-tumor exosomes has ...